Início › Linfoma Não Hodgkin › Texas › Dallas
Ensaios clínicos de Linfoma Não Hodgkin em Dallas, TX
17 estudos para Linfoma Não Hodgkin estão buscando participantes em locais em Dallas e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RecrutandoFase 2
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RecrutandoFase 1/2
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecrutandoFase 1
- University of Texas Southwestern, Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecrutandoFase 1
- Texas Oncology - DFW (Sammons CC), Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecrutandoFase 1
- Baylor University Medical Center, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecrutandoFase 1/2
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RecrutandoEstudo observacional
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
RecrutandoFase 2
- UT Southwestern Medical Center, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecrutandoEstudo observacional
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
RecrutandoFase 1/2
- University of Texas Southwestern Medical Center, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
RecrutandoFase 1
- University of Texas Southwestern, Dallas
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
RecrutandoFase 1
- UT Southwestern Medical Center, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RecrutandoEstudo observacional
- Ut Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Dallas
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
RecrutandoEstudo observacional
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecrutandoFase 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
RecrutandoFase 1/2
- UT Southwestern Medical Center, Dallas
Ensaios de Linfoma Não Hodgkin em outras cidades
- New York City, NY31 estudos
- Houston, TX31 estudos
- Boston, MA26 estudos
- Nashville, TN21 estudos
- Philadelphia, PA20 estudos
- Baldwin Park, CA19 estudos
- Washington, DC18 estudos
- Milwaukee, WI18 estudos
- Atlanta, GA18 estudos
- Chicago, IL18 estudos
- Columbus, OH18 estudos
- Seattle, WA16 estudos
Outros estudos em Dallas
- Câncer de Mama55 estudos
- Câncer de Pulmão de Não Pequenas Células52 estudos
- Câncer Metastático42 estudos
- Insuficiência Cardíaca42 estudos
- Câncer (todos os tipos)37 estudos
- Câncer de Próstata36 estudos
- Câncer Colorretal33 estudos
- Obesidade30 estudos
- Câncer de Ovário28 estudos
- Câncer de Pulmão27 estudos
- Câncer de Bexiga27 estudos
- Câncer Endometrial24 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.